ReportSwitzerland’s biotech sector defies tough markets with record revenueIf one follows the figures in the Swiss Biotech Report 2026, the green lights are more prominent than the red warning signals. The Swiss biotech industry continued its growth momentum in 2025 and even … more ➔
Sevan Habeshian & Christian Heinis et al. https://www.nature.com/articles/s41467-022-31428-Drug DesignMacrocycles: big is the new beautifulIn the evolving landscape of drug discovery and new design, scientists and pharmaceutical innovators continually strive to develop therapies that are both highly selective and clinically effective, … more ➔
Getty Images, for Unsplash+Asthma, COPDSwiss Windward Bio adds US$165m to its Chinese pipelineBasel-based Windward Bio did it again and has raised another three-digit millions – $165 million to be exact – to advance a pipeline of long-acting immunology therapies—much of it sourced through … more ➔
Venture CapitalCytospire raises £61M to take gamma-delta T-cell engager into the clinicCytospire Therapeutics has raised a £61 million (€71 million) Series A round, positioning the British biotech to advance pan-gamma-delta T-cell engagers (TCEs) into cancer clinical trials. more ➔
M&AUCB buys Candid Therapeutics for up to US$2.2bn to deepen autoimmune T-cell engager pushBelgian biopharma UCB has moved quickly from testing the waters in autoimmune T-cell engagers to making one of the largest bets yet on the modality, agreeing to acquire San Diego-based Candid Therapeutics … more ➔
Planet Volumes via Unsplash+FinancingBioOrbit: record seed round for in‑space drug manufacturingCan in‑space manufacturing help cancer patients take complex medicines at home? For a technology that aims to do just that, UK‑based BioOrbit has just raised £9.8m (around €11.3m) – the “world’s … more ➔
ValnevaFinancingValneva reels in €84m in fresh financing to shore up vaccine pipelineValneva SE, the French specialty‑vaccine developer, has completed an €84m reserved offering, adding a useful cash buffer just as the group enters a high‑risk window for its Lyme disease and shigellosis‑vaccine … more ➔
ServierVenture CapitalInside Servier’s new €200M venture fundWith the launch of Servier Ventures announced in January and a €200 million commitment to biotech investment, Servier is stepping up its engagement in early-stage innovation in oncology and neurology. … more ➔
Paris Bilal via Unsplash+AcquisitionChiesi in US$1.9bn deal to buy KalVista and its angioedema drugItalian pharma group Chiesi has struck a near‑US$1.9bn deal to acquire KalVista Pharmaceuticals, bringing the US biotech’s first‑in‑class oral treatment for hereditary angioedema into its rare‑disease … more ➔
A. C. via Unsplash+FinancingCoultreon bags US$125m for autoimmune pipelineBelgian Coultreon Biopharma has raised US$125m in a big‑pharma‑backed Series A round to push its first‑in‑class SIK3 inhibitor into Phase II after an ongoing Phase I programme in autoimmune … more ➔
Sevan Habeshian & Christian Heinis et al. https://www.nature.com/articles/s41467-022-31428-
Getty Images, for Unsplash+
Planet Volumes via Unsplash+
Valneva
Servier
Paris Bilal via Unsplash+
A. C. via Unsplash+